Magnus Hurst

Innovive, Inc. develops disposable caging products for mice and rats. The firm serves the global laboratory research market with products and services that allow animal research facilities to scientific discovery. It also offers information management products. The company was founded by Dee Conger in 2004 and is headquartered in San Diego, CA.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

Biolin Scientific AB develops, manufactures, markets, and sells analytical instruments and related products. Its parent company involves in the discovery of drugs, develops solutions for energy and materials, and performs research at the frontiers of science and technology. The firm's customers include companies working with pharmaceuticals, energy, chemicals, and advanced materials, as well as academic and governmental research institutes. The company was founded on September 19, 1984 and is headquartered in Vastra Frolunda, Sweden.

Yield Life Science AB engages in the investment and development of companies within the pharmaceutical and medical industries. Its portfolio company, Isofol Medical AB, focuses on the development of Modufolin, a rescue therapy for cancer patients. The company was founded by Anders Runo Hilmersson in 1992 and is headquartered in Gothenburg, Sweden.

Part of MVI London Ltd., MVI Sverige KB is a Swedish investment company. The company is based in Stockholm, Sweden. The company was founded by Lars Erik Lind.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium.

Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Lars Lind Holding AB provides financial services.

GOKAP Invest (GOKAP) is a venture capital operating division of GOKAP Invest AB founded in 2017 by Clementina Osterberg. The firm is headquartered in Gothenburg, Sweden.

GOKAP Invest AB provides investment services. The private company is based in Gothenburg, Sweden and has subsidiaries in Sweden. The Swedish company was founded in 2017. The CEO is Roy Peter Jonebrant.

Alain Oncologie Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Ad Bio Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The company is based in Paris, France. The CEO of the French company is Alain Herrera.

Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care.

EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed.

Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston.